FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.

@article{Cohen2005FDADA,
  title={FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.},
  author={Martin H. Cohen and John R. Johnson and Yong-cheng Wang and Rajeshwari Sridhara and Richard Pazdur},
  journal={The oncologist},
  year={2005},
  volume={10 6},
  pages={363-8}
}
On August 19, 2004, pemetrexed for injection (Alimta); Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com) received accelerated approval as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had received prior chemotherapy. Approval was primarily based on a single, controlled, unblinded trial. Five hundred seventy-one protocol-eligible patients were randomized to receive either pemetrexed or docetaxel (Taxotere… CONTINUE READING
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…